4.6 Article

Complement receptor 1 gene (CR1) intragenic duplication and risk of Alzheimer's disease

Journal

HUMAN GENETICS
Volume 137, Issue 4, Pages 305-314

Publisher

SPRINGER
DOI: 10.1007/s00439-018-1883-2

Keywords

-

Funding

  1. Alzheimer's Research UK
  2. Schools of Life Sciences and Medicine, University of Nottingham, Nottingham, NG7 2UH, UK
  3. Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Manchester, M13 9PT, UK
  4. Centre for Public Health, School of Medicine, Queen's University Belfast, BT9 7BL, UK
  5. Department of Psychiatry, University of Bonn, Bonn, Germany
  6. School of Clinical Sciences, John James Laboratories, University of Bristol, Bristol, BS16 1LE, UK
  7. Emma R. L. C. VardySalford Royal NHS Foundation Trust
  8. Cerebral Function Unit, Greater Manchester Neurosciences Centre, Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK
  9. University of Oxford (OPTIMA), Oxford, OX3 9DU, UK
  10. Clinical and Experimental Science, University of Southampton, Southampton, SO17 1BJ, UK

Ask authors/readers for more resources

Single nucleotide variants (SNVs) within and surrounding the complement receptor 1 (CR1) gene show some of the strongest genome-wide association signals with late-onset Alzheimer's disease. Some studies have suggested that this association signal is due to a duplication allele (CR1-B) of a low copy repeat (LCR) within the CR1 gene, which increases the number of complement C3b/C4b-binding sites in the mature receptor. In this study, we develop a triplex paralogue ratio test assay for CR1 LCR copy number allowing large numbers of samples to be typed with a limited amount of DNA. We also develop a CR1-B allele-specific PCR based on the junction generated by an historical non-allelic homologous recombination event between CR1 LCRs. We use these methods to genotype CR1 and measure CR1-B allele frequency in both late-onset and early-onset cases and unaffected controls from the United Kingdom. Our data support an association of late-onset Alzheimer's disease with the CR1-B allele, and confirm that this allele occurs most frequently on the risk haplotype defined by SNV alleles. Furthermore, regression models incorporating CR1-B genotype provide a better fit to our data compared to incorporating the SNV-defined risk haplotype, supporting the CR1-B allele as the variant underlying the increased risk of late-onset Alzheimer's disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available